FREE subscriptions for doctors and students... click here
You have 3 more open access pages.
Risperidone is aan antipsychotic agent which has mixed dopamine D2 receptor
and serotonin S2 receptor blocking activities.
- indicated for first onset and acutely relapsed patients
- the blocking of 5HT2 receptors means that it may also selectively relieve negative symptoms - other drugs with the same receptor action have been shown to do this
- has a lower incidence of extra-pyramidal side-effects than conventional anti-psychotics
Note that (1):
- risperidone is not licensed for the treatment of behavioural symptoms
- risperidone is not recommended for the treatment of behavioural symptoms
of dementia because of an increased risk of cerebrovascular adverse events
(including cerebrovascular accidents and transient ischaemic attacks
- data from randomised clinical trials conducted in the elderly
(> 65 years) patients with dementia indicate that there is an approximately
3-fold increased risk of cerebrovascular adverse events (including
cerebrovascular accidents and transient ischaemic attacks) with risperidone,
compared with placebo. Cerebrovascular adverse events occurred in
3.3% (33/989) of patients treated with risperidone and 1.2% (8/693)
of patients treated with placebo. The Odds Ratio was 2.96 (1.33, 7.45
- 95% confidence interval)
- Janssen-Cilag Limited (12th March 2004). The risk of cerebrovascular adverse
events in elderly patients with dementia:- important changes to the Summary
of Product Characteristics relating to the use of risperidone.
- Prescribers' Journal (1999); 39 (3): 154-159.
Last reviewed 01/2018